ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is ZIOPHARM Oncology. And to talk to us a little bit about the company is CEO, Larry Cooper -- sorry, Laurence Cooper. My mistake. The breakout session with the Q&A will be in the Yorkshire room. With that, Laurence.
Thanks very much, Eric, and greetings from San Francisco. Forward-looking statements and additional information on our website.
Ziopharm is an independent, and we stress independent, immuno-oncology company focused on developing individualized and cost-effective therapies primarily aimed at the large and unmet needs in solid tumors. The key words on there are independent and that we are focused on solid tumors as we move forward, and I'll get into the technical reasons and the programmatic reasons of why we're so bullish on our company.
We have technologies that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |